Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inari Medical, Inc. - Common Stock (NQ: NARI )

79.30 -0.15 (-0.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inari Medical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades See all analyst ratings upgrades. 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Inari Medical: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last... 
Via Benzinga
Inari Medical's Return On Capital Employed Insights
Benzinga Pro data, Inari Medical (NASDAQ:NARI) reported Q1 sales of $86.75 million. Earnings fell to a loss of $3.13 million, resulting in a 382.66% decrease from last quarter. 
Via Benzinga
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Via Benzinga
Inari Medical: Battling Blood Clots
Inari Medical is a small medical outfit whose stock has gone through the wringer for nearly a year — but the story remains terrific and the stock is starting to act better. Let's take a closer look. 
Via Talk Markets
Recap: Inari Medical Q4 Earnings
Inari Medical (NASDAQ:NARI) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
A Preview Of Inari Medical's Earnings
Inari Medical (NASDAQ:NARI) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Inari... 
Via Benzinga
Inari Medical Reports Mixed Q4 Earnings, Guides FY22 Sales Above Consensus
Inari Medical Inc's (NASDAQ: NARI) Q4 revenue was $83.2 million, up 14% sequentially and 71% Y/Y, beating the consensus of $78.16 million. The sequential growth was... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
A Preview Of Inari Medical's Earnings
Inari Medical (NASDAQ:NARI) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.... 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo... 
Via Benzinga
21 Stocks Moving in Tuesday's Pre-Market Session
Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from... 
Via Benzinga
Inari Medical Reports Solid Preliminary Q4, FY21 Sales
Inari Medical Inc (NASDAQ: NARI) expects Q4 FY21 sales of $82.8 million - $83.3 million, up 14% sequentially and 71% year-over-year (at the midpoint of the range),... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Inari Medical (NASDAQ:NARI) stock... 
Via Benzinga
Inari Medical, Inc. (NARI) Q3 2021 Earnings Call Transcript
NARI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Recap: Inari Medical Q3 Earnings
Inari Medical (NASDAQ:NARI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
3 Under-the-Radar COVID Stocks
Some COVID-19 stocks are pretty famous. But other lesser-known names are flying high, too. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
President And CEO Of Inari Medical Makes $2.4M Sale
William Hoffman, President And CEO at Inari Medical (NASDAQ:NARI), made a large insider sell on October 7, according to a new SEC filing. What Happened: A Form 4 filing from the... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Inari Medical Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, Inari Medical (NASDAQ:NARI) showed a loss in earnings since Q1, totaling $4.11 million. Sales, on the other hand, increased by 10.55% to $63.45... 
Via Benzinga
Wall Street Thinks This Healthcare Stock Could Double Your Money in the Next Year
Even the median estimate would be a 70% gain. 
Via The Motley Fool
This Healthcare Company Just Shocked Its Investors
The stock price is collapsing as a result. 
Via The Motley Fool
Inari Medical Plunged 15% After Mixed Q2 Earnings, Lifting FY21 Sales Guidance
Inari Medical Inc's (NASDAQ: NARI) Q2 revenue was $63.5 million, more than doubled from $25.4 million in Q2 FY20, beating the consensus of $59.6 million. The growth... 
Via Benzinga
Dow, S&P 500 Extend Highs After CPI Reading
The Dow and S&P 500 both nabbed intraday record highs today, the Nasdaq slipped lower. 
Via Talk Markets
Topics Stocks
Exposures US Equities
66 Biggest Movers From Yesterday
Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.